FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.68% | -1,055.60% | -618.71% | 41.30% | 68.11% |
| Total Depreciation and Amortization | 52.94% | 61.54% | 47.14% | 17.52% | 17.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 678.29% | 168.80% | 109.34% | -70.10% | -98.02% |
| Change in Net Operating Assets | -378.85% | 231.82% | -203.46% | -471.12% | -187.74% |
| Cash from Operations | -2.93% | -52.42% | -104.62% | -23.39% | -91.94% |
| Capital Expenditure | 100.00% | 45.45% | -222.73% | -437.50% | -4,850.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 45.45% | -222.73% | -437.50% | -4,850.00% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -2,856.52% | -- | -- | -- | -- |
| Issuance of Common Stock | 14,544.44% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -65.81% | -100.00% | 2,643.60% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.56% | -314.56% | 108.15% | -429.15% | 484.15% |